| ［1］ |
中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识（2021版）［J］. 中华皮肤科杂志, 2021,54（2）:105⁃109. doi: 10.35541/cjd.20200785.
|
| ［2］ |
van Geel N, Passeron T, Wolkerstorfer A, et al. Reliability and validity of the Vitiligo Signs of Activity Score （VSAS）［J］. Br J Dermatol, 2020,183（5）:883⁃890. doi: 10.1111/bjd.18950.
|
| ［3］ |
Speeckaert R, Speeckaert M, De Schepper S, et al. Biomarkers of disease activity in vitiligo: a systematic review［J］. Autoimmun Rev, 2017,16（9）:937⁃945. doi: 10.1016/j.autrev. 2017.07.005.
|
| ［4］ |
Goh BK, Pandya AG. Presentations, signs of activity, and differential diagnosis of vitiligo［J］. Dermatol Clin, 2017,35（2）:135⁃144. doi: 10.1016/j.det.2016.11.004.
|
| ［5］ |
Xiang W, Xu A, Xu J, et al. In vivo confocal laser scanning microscopy of hypopigmented macules: a preliminary comparison of confocal images in vitiligo, nevus depigmentosus and postinflammatory hypopigmentation［J］. Lasers Med Sci, 2010,25（4）:551⁃558. doi: 10.1007/s10103⁃010⁃0764⁃2.
|
| ［6］ |
Ibrahim S, Hegazy RA, Gawdat HI, et al. Differentiating active from stable vitiligo: the role of dermoscopic findings and their relation to CXCL10［J］. J Cosmet Dermatol, 2022,21（10）:4651⁃4658. doi: 10.1111/jocd.14922.
|
| ［7］ |
Bae JM, Oh SH, Kang HY, et al. Development and validation of the Vitiligo Extent Score for a Target Area （VESTA） to assess the treatment response of a target lesion［J］. Pigment Cell Melanoma Res, 2019,32（2）:315⁃319. doi: 10.1111/pcmr.12730.
|
| ［8］ |
Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV⁃B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index［J］. Arch Dermatol, 2004,140（6）:677⁃683. doi: 10.1001/archderm.140. 6.677.
|
| ［9］ |
Komen L, da Graça V, Wolkerstorfer A, et al. Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo［J］. Br J Dermatol, 2015,172（2）:437⁃443. doi: 10.1111/bjd.13432.
|
| ［10］ |
Chaweekulrat P, Silpa⁃Archa N, Apinuntham C, et al. Reliability, validity and feasibility of the Vitiligo Extent Score （VES） and Self⁃Assessment Vitiligo Extent Score （SA⁃VES） among vitiligo patients: a cross⁃cultural validation［J］. Clin Cosmet Investig Dermatol, 2021,14:949⁃957. doi: 10.2147/CCID.S324073.
|
| ［11］ |
Renert⁃Yuval Y, Ezzedine K, Grimes P, et al. Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients［J］. JAMA Dermatol, 2024,160（4）:453⁃461. doi: 10.1001/jamadermatol. 2024.0021.
|
| ［12］ |
Hu W, Xu Y, Ma Y, et al. Efficacy of the topical calcineurin inhibitors tacrolimus and pimecrolimus in the treatment of vitiligo in infants under 2 years of age: a randomized, open⁃label pilot study［J］. Clin Drug Investig, 2019,39（12）:1233⁃1238. doi: 10.1007/s40261⁃019⁃00845⁃x.
|
| ［13］ |
Al⁃Smadi K, Ali M, Alavi SE, et al. Using a topical formulation of vitamin D for the treatment of vitiligo: a systematic review［J］. Cells, 2023,12（19）:2387. doi: 10.3390/cells12192387.
|
| ［14］ |
Plachouri KM, Kyriakou G, Chourdakis V, et al. One stone, two birds: improvement of early⁃onset vitiligo under apremilast in a patient with plaque psoriasis［J］. Dermatol Ther, 2019,32（5）:e13064. doi: 10.1111/dth.13064.
|
| ［15］ |
Sun X, Sheng A, Xu AE. Successful treatment of vitiligo with crisaborole ointment: a report of two cases［J］. Br J Dermatol, 2023,188（3）:436⁃437. doi: 10.1093/bjd/ljac092.
|
| ［16］ |
Yuksel EP, Aydin F, Senturk N, et al. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase⁃superoxide dismutase treatment in vitiligo patients［J］. Eur J Dermatol, 2009,19（4）:341⁃344. doi: 10.1684/ejd.2009.0699.
|
| ［17］ |
Hu W, Zhang L, Lin F, et al. Topical epigallocatechin⁃3⁃gallate in the treatment of vitiligo［J］. Australas J Dermatol, 2021,62（3）:e404⁃e407. doi: 10.1111/ajd.13612.
|
| ［18］ |
Lee J, Chu H, Lee H, et al. A retrospective study of methylprednisolone mini ⁃ pulse therapy combined with narrow band UVB in non⁃segmental vitiligo［J］. Dermatology, 2016,232（2）:224⁃229. doi: 10.1159/000439563.
|
| ［19］ |
Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review［J］. Front Immunol, 2021,12:790125. doi: 10.3389/fimmu.2021.790125.
|
| ［20］ |
Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial［J］. J Am Acad Dermatol, 2023,88（2）:395⁃403. doi: 10.1016/j.jaad.2022.11.005.
|
| ［21］ |
Su X, Luo R, Ruan S, et al. Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo［J］. J Am Acad Dermatol, 2023,89（6）:1257⁃1259. doi: 10.1016/j.jaad.2023.07.1016.
|
| ［22］ |
Phan K, Phan S, Shumack S, et al. Repigmentation in vitiligo using Janus kinase （JAK） inhibitors with phototherapy: systematic review and meta⁃analysis［J］. J Dermatolog Treat, 2022,33（1）:173⁃177. doi: 10.1080/09546634.2020.1735615.
|
| ［23］ |
Mohammad TF, Al⁃Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo［J］. J Am Acad Dermatol, 2017,76（5）:879⁃888. doi: 10.1016/j.jaad.2016.12.041.
|
| ［24］ |
林洁, 樊奇敏, 许爱娥. 窄谱中波紫外线治疗白癜风平台期相关研究［J］. 临床皮肤科杂志, 2016,45（6）:465⁃468. doi: 10.16761/j.cnki.1000⁃4963.2016.06.025.
|
| ［25］ |
Zhang D, Wei X, Hong W, et al. A retrospective study of long term follow⁃up of 2283 vitiligo patients treated by autologous, non⁃cultured melanocyte⁃keratinocyte transplantation［J］. Aging （Albany NY）, 2021,13（4）:5415⁃5425. doi: 10.18632/aging.202472.
|
| ［26］ |
Seneschal J, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force⁃Part 2: specific treatment recommendations［J］. J Eur Acad Dermatol Venereol, 2023,37（11）:2185⁃2195. doi: 10.1111/jdv.19450.
|
| ［27］ |
Hu W, Lin F, Lei J, et al. Impacts of exposure to topical calcineurin inhibitors on metabolism in vitiligo infants［J］. Pediatr Res, 2023,93（3）:661⁃665. doi: 10.1038/s41390⁃022⁃02133⁃5.
|
| ［28］ |
Oiso N, Kawada A. Freckling promoted by topical tacalcitol in a Japanese boy with left eyelid vitiligo［J］. Pediatr Dermatol, 2012,29（5）:671⁃672. doi: 10.1111/j.1525⁃1470.2011.01559.x.
|
| ［29］ |
Chi CC, Wang SH, Kirtschig G. Safety of topical corticosteroids in pregnancy［J］. JAMA Dermatol, 2016,152（8）:934⁃935. doi: 10.1001/jamadermatol.2016.1009.
|
| ［30］ |
Mukhatayev Z, Le Poole IC. Vitiligo: advances in pathophysiology research and treatment development［J］. Trends Mol Med, 2024,30（9）:844⁃862. doi: 10.1016/j.molmed.2024.04.009.
|
| ［31］ |
Richmond JM, Strassner JP, Zapata L Jr, et al. Antibody blockade of IL⁃15 signaling has the potential to durably reverse vitiligo［J］. Sci Transl Med, 2018,10（450）:eaam7710. doi: 10.1126/scitranslmed.aam7710.
|
